A

ABL Bio Inc
KOSDAQ:298380

Watchlist Manager
ABL Bio Inc
KOSDAQ:298380
Watchlist
Price: 190 600 KRW -5.17% Market Closed
Market Cap: 10.5T KRW

ABL Bio Inc
Investor Relations

ABL Bio, Inc. engages in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2018-12-19. The major products include anti-angiogenesis antibodies anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, antibody-drug conjugates (ADCs) , among others.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Dr. Sang Hoon Lee Ph.D.
Founder, President & CEO
No Bio Available
Mr. Jaecheon Lee M.B.A., MBA
Executive VP, MD & CFO
No Bio Available
Mr. Jung Dae Kim M.B.A.
Executive VP & COO
No Bio Available
Dr. You Weon-Kyoo PH.D.
Executive VP, Chief Scientific Officer & Head of R&D
No Bio Available
Dr. Jaeho Jung Ph.D.
Executive VP & Chief of Discovery
No Bio Available
Dr. Jong Hwa Won Ph.D.
Executive VP, Chief Translational Research Officer & Head of Early Development
No Bio Available
Dr. Eunkyung Kim M.D., Ph.D.
Head of Medical & Clinical Development
No Bio Available

Contacts

Address
GYEONGGI-DO
Seongnam
2F, 16, Daewangpangyo-ro 712beon-gil, Bundang-gu
Contacts
+823180189800
www.ablbio.com